Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $97

Benzinga · 2d ago
Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $89 to $97.